GE HealthCare announced on October 5, 2026, that it agreed to purchase SOFIE Biosciences from private equity firm Trilantic North America for $945 million in cash. SOFIE Biosciences operates as a contract manufacturing organization producing positron emission tomography radiopharmaceuticals. The transaction gives the buyer a network of 15 manufacturing sites and 21 cyclotrons across the United States. GE HealthCare will integrate the business into its pharmaceutical diagnostics segment to control the final stages of drug delivery to patients. The arrangement includes the United States rights to FAPI-74, a Phase III diagnostic radiotracer aimed at identifying multiple cancer types.
The transaction demonstrates a structural shift in how medical technology companies approach the theranostics supply chain. Radiopharmaceuticals possess extremely short half-lives, often requiring administration within hours of production. By bringing manufacturing capacity in-house, large diagnostics providers reduce their reliance on fragmented third-party networks. This vertical integration allows buyers to capture higher margins while ensuring consistent supply for their own proprietary imaging agents. The transaction also suggests that private equity firms see current valuations in the precision medicine sector as an optimal exit window following periods of aggressive capacity expansion.
SOFIE Biosciences generates revenue by running cyclotrons that create fluorine-18 labeled isotopes, which decay with a half-life of 110 minutes. According to an October 5 press release from GE HealthCare, the acquirer expects the acquired business to grow at a low double-digit rate in its first full year of ownership. This specific growth projection reveals that the acquirer models immediate operational synergies rather than treating the purchase as a passive infrastructure investment. The short decay time forces production to happen within a tight geographic radius of the imaging center, making physical site footprint the primary constraint on market share in this sector.
Deal terms at a glance
The October 5 announcement from GE HealthCare details the primary financial terms. The buyer pays entirely in cash to secure full ownership of the target company. The business will become part of the pharmaceutical diagnostics division after regulatory clearance.
| Acquirer | GE HealthCare |
| Target | SOFIE Biosciences |
| Seller | Trilantic North America |
| Purchase price | $945 million |
| Implied enterprise value | $945 million |
| Consideration | 100% cash |
| Premium | Not disclosed |
| Financing | Cash on hand |
| Conditions | Customary regulatory approvals |
| Expected timetable | First half of 2027 |
The $945 million cash price establishes a strict baseline for the transaction. GE HealthCare expects the purchase to increase its adjusted earnings before interest and taxes margin during the first year. The cash structure avoids shareholder dilution for the buyer. By acquiring the entirety of the equity from Trilantic North America and the founders, the acquirer assumes full control over the 15 contract manufacturing sites and the clinical pipeline. According to a September 18, 2026, report by Seeking Alpha, the buyer aims to operate the target as an independent manufacturing partner to third parties while supplying its own needs.
Advisers
GE HealthCare engaged three financial institutions to guide the transaction. BofA Securities provided primary financial advice, according to the October 5 press release from the buyer. Consello Financial LLC and Solomon Partners Securities LLC also acted as financial advisers to the acquiring company. Neither SOFIE Biosciences nor Trilantic North America disclosed their financial advisers in the primary announcements or subsequent filings.
How the deal came about
The relationship between the two entities began through a commercial partnership. In October 2023, GE HealthCare signed an exclusive global licensing agreement with SOFIE Biosciences. The 2023 arrangement granted the larger company global rights to the gallium-68 based radiotracer FAPI-46 and the rights outside the United States for the fluorine-18 based radiotracer FAPI-74. The target company retained clinical development and commercialization rights for FAPI-74 within the United States market. This initial licensing deal allowed the buyer to evaluate the target’s pipeline and operational capabilities over a three-year period.
Trilantic North America initiated its involvement with SOFIE Biosciences in 2024. The private equity firm purchased a 25.8% interest in the target company, according to a September 13, 2026, report by TradingView. The private equity backer funded capacity expansion across the manufacturing network. The capital injection enabled the target to increase its cyclotron count to 21 units.
In mid-2026, market rumors began circulating regarding a potential sale. The Financial Times reported on September 13, 2026, that the two companies were in advanced discussions for a purchase price of approximately $1 billion. The target’s founders and executives still held the majority of the equity alongside Trilantic North America during these negotiations. The discussions culminated in the definitive agreement announced on October 5, 2026.
Valuation and comparables
The $945 million purchase price implies a substantial increase in enterprise value since the private equity investment. When Trilantic North America acquired its 25.8% stake in 2024, the transaction valued the total business at up to $550 million, according to the September 13 report by TradingView. The new price represents an approximate 71% increase in valuation over two years. Neither party disclosed specific revenue or earnings multiples for the current transaction.
The radiopharmaceutical sector has seen aggressive valuation multiples in recent years as large pharmaceutical companies pursue theranostics assets. In 2023, Eli Lilly paid $1.4 billion in cash for Point Biopharma Global to acquire a network of manufacturing facilities and clinical-stage radioligand therapies. Point Biopharma traded at significant multiples of its future expected revenue based on its phase III prostate cancer asset. Similarly, Novartis acquired Mariana Oncology for $1 billion upfront in May 2024, securing early-stage radiopharmaceutical development capabilities.
While those comparable deals focused primarily on drug discovery, the SOFIE Biosciences transaction blends pharmaceutical development with heavy infrastructure. The target company operates 15 physical sites. GE HealthCare Chief Executive Officer Peter Arduini stated in 2026 that the company targets acquisitions that offer margins in the 30% range and high single-digit revenue growth. RBC Capital analyst Matthew Sykes published a note on October 5 stating that the acquisition fits the buyer’s capital allocation strategy and supports its long-range plan of 4% to 6% mid-single-digit growth. Investing.com reported on October 5 that RBC Capital maintained an $80 price target on the buyer’s stock following the announcement.
Financing and structure
GE HealthCare will fund the $945 million purchase entirely with cash. The buyer did not announce any new debt issuance or equity offerings to support the transaction. The acquirer reported organic revenue growth of 3.5% in the second quarter of 2026, generating $5.29 billion in total revenue, according to an October 5 report by Investing.com. This cash flow generation supports the all-cash consideration without stressing the buyer’s balance sheet.
The structural integration plans maintain the target’s existing third-party contracts. The buyer confirmed in its October 5 press release that SOFIE Biosciences will continue to operate as an independent manufacturing partner to its current customers. This means the target will still supply products from competing radiopharmaceutical providers. The buyer integrates the business into its pharmaceutical diagnostics segment, which supplies contrast media and molecular imaging agents.
Risks, conditions and key dates
The transaction faces several standard completion hurdles before the buyer can take control of the assets. The parties established a timeline extending into the next calendar year to resolve these matters.
- October 5, 2026: The companies sign and announce the definitive agreement.
- Late 2026: The parties submit required filings to antitrust regulators in the United States.
- First half of 2027: The transaction closes, assuming all regulatory conditions are met.
The primary risk involves antitrust scrutiny in the United States medical supply market. The buyer already holds a dominant position in diagnostic imaging equipment and contrast agents. By purchasing a major contract manufacturer, the acquirer gains control over the supply chain used by its competitors. The commitment to maintain third-party manufacturing contracts mitigates this regulatory risk. Another operational risk centers on the clinical trials for FAPI-74. The phase III asset requires approval from the United States Food and Drug Administration before it can generate commercial product revenue. If the clinical trial fails to meet its endpoints, the buyer will lose the projected growth from the diagnostic agent.
Where reports disagree
Initial reports regarding the transaction size differed from the final confirmed price. On September 13, 2026, the Financial Times reported that the two companies discussed a purchase price of approximately $1 billion. Fierce Biotech repeated the $1 billion figure on the same day. The final definitive agreement announced on October 5 set the exact cash purchase price at $945 million, according to the GE HealthCare press release. Seeking Alpha and Investing.com both confirmed the $945 million final figure on October 5.
